4-bromobutyl(triphenyl)-λ5-phosphane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromobutyl(triphenyl)-λ5-phosphane
• 化学式: C₂₂H₂₄BrP
• 分子量: 399.31
• InChiKey: HNFCHUHOCQIEIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  4-bromobutyl(triphenyl)-λ5-phosphane 、 4-甲氧基苯甲醛 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以80%的产率得到
  参考文献：
  名称：

  钴催化烯烃的Z到E异构化：（E）-β取代的苯乙烯的一种方法。

  摘要：

  开发了使用酰胺基-二膦配体的高效钴催化的β-取代的苯乙烯的Z到E异构化方法，提供了具有良好功能耐受性和高立体选择性的（E）异构体。使用（Z）-和（E）-烯烃的混合物作为起始原料，该反应可以在催化剂负载为0.1mol％的情况下按比例放大至克级。初步的机理研究表明，在实验和DFT计算的支持下，钴（I）氢化物和苄基钴可能参与了反应。

  DOI：

  10.1021/acs.orglett.0c00072

文献信息

• BISTRIFILATE-BASED FLUOROGENIC PROBES FOR DETECTION OF SUPEROXIDE ANION RADICAL
  申请人：Yang Dan

  公开号：US20150219676A1

  公开（公告）日：2015-08-06

  The invention provides fluorogenic compounds and probes that can be used as reagents for measuring, detecting and/or screening superoxide. The fluorogenic compounds of the invention can produce fluorescence colors, such as green, yellow, red, or far-red. The invention further provides fluorogenic compounds for selectively staining superoxide in the mitochondria of living cells. The invention also provides methods that can be used to measure, directly or indirectly, the presence and/or amount of superoxide in chemical samples and biological samples such as cells and tissues in living organisms, and a high-throughput screening methods for detecting or screening superoxide or compounds that can increase or decrease the level of superoxide in chemical and biological samples.

  该发明提供了可以用作测量、检测和/或筛选超氧化物的试剂的荧光化合物和探针。该发明的荧光化合物可以产生荧光颜色，如绿色、黄色、红色或远红色。该发明进一步提供了用于选择性染色活细胞线粒体中超氧化物的荧光化合物。该发明还提供了可用于直接或间接测量化学样品和生物样品中超氧化物的存在和/或量的方法，例如生物体内的细胞和组织，以及用于检测或筛选化学和生物样品中超氧化物或可以增加或减少超氧化物水平的化合物的高通量筛选方法。
• Benzazepine Dicarboxamide Compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160257653A1

  公开（公告）日：2016-09-08

  This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R 1 to R 4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

  这项发明涉及一种新型苯并哒唑二羧酰胺化合物，其化学式如下，其中R1至R4如描述和索赔中定义，以及其药学上可接受的盐。这些化合物是TLR激动剂，因此可能作为治疗癌症、自身免疫疾病、炎症、败血症、过敏、哮喘、移植排斥、移植物抗宿主病、免疫缺陷和传染病等疾病的药物而有用。
• MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES
  申请人：Partikula LLC

  公开号：US20180028647A1

  公开（公告）日：2018-02-01

  Compositions of a modulator of cell metabolism, typically targeting cellular glycolysis, preferably with a targeting moiety, attached directly or indirectly to the inhibitor, or to a nanoparticle or other delivery vehicle thereof, and methods of use for treating cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases are provided. Pharmaceutical compositions including the targeted modulator and a pharmaceutically acceptable carrier are also provided. The pharmaceutical compositions can be administered to a subject in need thereof in an effective amount to reduce one or symptoms of the cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases alone or prior to or in conjunction with a further therapy such as radiotherapy.

  提供了细胞代谢调节剂的组成，通常以靶向细胞糖酵解为目标，最好带有一个靶向基团，直接或间接连接到抑制剂，或连接到纳米颗粒或其他递送载体上，并提供了用于治疗癌症、增生性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的方法。还提供了包括靶向调节剂和药学上可接受的载体的药物组合物。这些药物组合物可以以有效剂量给需要的受试者使用，以减少癌症、增生性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的症状之一或多个，独立使用或在放疗等进一步治疗之前或同时使用。
• [EN] USE OF COMPOUNDS FOR MAKING PRODUCTS WITH AT LEAST ONE N-HALAMINE PRECURSOR GROUP AND AT LEAST ONE CATIONIC CENTER<br/>[FR] UTILISATION DE COMPOSÉS POUR LA FABRICATION DE PRODUITS AVEC AU MOINS UN GROUPE PRÉCURSEUR DE N-HALAMINE ET AU MOINS UN CENTRE CATIONIQUE
  申请人：EXIGENCE TECH INC

  公开号：WO2019200478A1

  公开（公告）日：2019-10-24

  The present disclosure relates to using 2,2,6,6-tetramethyl-4-piperidone (TMPD) as a reactant in at least one chemical reaction for making a reaction-product compound that comprises at least one cyclic N-halamine precursor group and at least one cationic center, and optionally a coating incorporation group. The present disclosure also relates to using TMPD as a reactant in at least one chemical reaction for making: (a) an intermediate compound that comprises at least one cyclic N-halamine precursor group and at least one coating incorporation group, (b) an intermediate compound that comprises at least one cyclic N-halamine precursor group and at least one cationic center, or (c) an intermediate compound that comprises at least one cyclic N-halamine precursor group, at least one coating incorporation group, and at least one cationic center. The compounds disclosed herein may have biocidal activity, and/or they may have increased biocidal activity following one or more chemical-modification reactions.

  本公开涉及在至少一种化学反应中使用2,2,6,6-四甲基-4-哌啶酮（TMPD）作为反应物，以制备包含至少一个环状N-卤胺前体基团和至少一个阳离子中心的反应产物化合物，以及可选的涂层结合基团。本公开还涉及在至少一种化学反应中使用TMPD作为反应物，以制备：（a）至少包含一个环状N-卤胺前体基团和至少一个涂层结合基团的中间化合物，（b）至少包含一个环状N-卤胺前体基团和至少一个阳离子中心的中间化合物，或（c）至少包含一个环状N-卤胺前体基团、至少一个涂层结合基团和至少一个阳离子中心的中间化合物。本文披露的化合物可能具有杀菌活性，或者它们可能在一个或多个化学修饰反应后具有增强的杀菌活性。
• MITOCHONDRIA-TARGETED THERANOSTIC AGENTS
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20150336993A1

  公开（公告）日：2015-11-26

  Mitochondria-targeted theranostic agents and methods of using them diagnostically and therapeutically are disclosed. In particular, the invention relates to theranostic agents comprising F16, or analogues thereof, conjugated to alkyltriphenylphosphonium lipophilic cations, and their uses in medical imaging and treatment of diseases associated with mitochondrial dysfunction, including cancer.

  本发明涉及定向线粒体治疗剂和使用它们进行诊断和治疗的方法。特别是，本发明涉及包含F16或其类似物与烷基三苯基膦脂溶性阳离子偶联的治疗剂，以及它们在医学成像和治疗与线粒体功能障碍有关的疾病，包括癌症方面的应用。